MCA Stability Tool

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Accord-UK Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Alliance Healthcare (Distribution) Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (CST Pharma Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Medihealth (Northern) Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Phoenix Healthcare Distribution Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Rivopharm (UK) Ltd)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Compatible

Aceclofenac 100mg tablets (Sigma Pharmaceuticals Plc)

Explore other Aceclofenac formulations Explore other Aceclofenac 100mg tablets suppliers

Stability Notes

No stability data in MCAs available but no theoretical concerns with product.

Provenance

This recommendation is based on the products Preservex 100mg film coated tablets (Almirall Limited) and Aceclofenac 100mg film coated tablets (Rivopharm UK Ltd).

Print this list

Compatible

Medicines suitable for use in MCAs, although use is likely to be off-label.  Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed).  Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices.  Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Use with caution

There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.

Incompatible

Medicines under this category are not suitable for use in MCAs.

No Stability Information

These medicines have not been reviewed by SPS.